Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot may replace hours of infusion for heart attack care

NCT ID NCT01080638

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of the drug abciximab given directly into the heart artery works as well as the standard approach of a dose into a vein followed by a 12-hour infusion. The goal was to reduce heart muscle damage in people having their first non-ST elevation heart attack. The trial was terminated early, so results are incomplete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abciximab
What this could lead to
If it works, this could simplify treatment for certain heart attacks by using a single injection instead of a long infusion.
What could go wrong
The trial was terminated early, so results are limited. It only included first-time heart attack patients, so findings may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

150 people

The number who actually took part.

Started

Aug 2009

Finished

Dec 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * non-ST segment elevation acute myocardial infarction * within 48 hours presence of chest pain * Troponin-T or I positive before CAG * First myocardial infarction * will be performed coronary angioplasty Exclusion Criteria: * under 18 years of age,80 years or older * Bleeding tendency * History of major surgery within 4 weeks * Major stroke within 2 years * Thrombocytopenia (\<120,000 / uL) * Cardiogenic shock * Known allergy to aspirin, heparin, or abciximab * Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc) * Chronic atrial fibrillation * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angioplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute subendocardial myocardial infarction myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angioplasty Myocardial infarction

Contacts and locations

Locations

  • Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.